Cvrx Inc (CVRX)

$21.92

+1.45

(+7.08%)▲

Market is closed - opens 8 PM, 04 Dec 2023

Performance

  • $20.31
    $22.20
    $21.92
    downward going graph

    7.34%

    Downside

    Day's Volatility :8.51%

    Upside

    1.26%

    downward going graph
  • $6.57
    $21.92
    $21.92
    downward going graph

    70.03%

    Downside

    52 Weeks Volatility :70.03%

    Upside

    0.0%

    downward going graph

Returns

PeriodCvrx Inc
3 Months
27.37%
6 Months
73.28%
1 Year
51.8%
3 Years
18.23%

Highlights

Market Capitalization
419.4M
Book Value
$3.98
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.06
Wall Street Target Price
20.4
Profit Margin
-121.06%
Operating Margin TTM
-90.65%
Return On Assets TTM
-24.1%
Return On Equity TTM
-42.35%
Revenue TTM
35.2M
Revenue Per Share TTM
1.7
Quarterly Revenue Growth YOY
69.89999999999999%
Gross Profit TTM
17.5M
EBITDA
-44.4M
Diluted Eps TTM
-2.06
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.1
EPS Estimate Next Year
-2.06
EPS Estimate Current Quarter
-0.58
EPS Estimate Next Quarter
-0.57

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Cvrx Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 6.93%

Current $21.92
Target $20.40

Company Financials

FY19Y/Y Change
Revenue
6.3M
-
Net Income
-14.6M
-
Net Profit Margin
-233.87%
-
FY20Y/Y Change
Revenue
6.1M
↓ 3.26%
Net Income
-14.1M
↓ 3.58%
Net Profit Margin
-233.09%
↑ 0.78%
FY21Y/Y Change
Revenue
13.0M
↑ 115.36%
Net Income
-43.1M
↑ 205.32%
Net Profit Margin
-330.45%
↓ 97.36%
FY22Y/Y Change
Revenue
22.5M
↑ 72.36%
Net Income
-41.4M
↓ 3.83%
Net Profit Margin
-184.38%
↑ 146.07%
Q2 FY22Q/Q Change
Revenue
5.0M
↑ 23.43%
Net Income
-11.1M
↑ 10.81%
Net Profit Margin
-220.06%
↑ 25.06%
Q3 FY22Q/Q Change
Revenue
6.2M
↑ 22.96%
Net Income
-9.8M
↓ 11.21%
Net Profit Margin
-158.91%
↑ 61.15%
Q4 FY22Q/Q Change
Revenue
7.2M
↑ 16.0%
Net Income
-10.5M
↑ 7.18%
Net Profit Margin
-146.82%
↑ 12.09%
Q1 FY23Q/Q Change
Revenue
8.0M
↑ 11.19%
Net Income
-11.4M
↑ 7.95%
Net Profit Margin
-142.55%
↑ 4.27%
Q2 FY23Q/Q Change
Revenue
9.5M
↑ 19.06%
Net Income
-11.7M
↑ 2.44%
Net Profit Margin
-122.64%
↑ 19.91%
Q3 FY23Q/Q Change
Revenue
10.5M
↑ 10.64%
Net Income
-9.0M
↓ 22.66%
Net Profit Margin
-85.73%
↑ 36.91%
FY19Y/Y Change
Total Assets
29.1M
-
Total Liabilities
308.2M
-
FY20Y/Y Change
Total Assets
64.8M
↑ 122.55%
Total Liabilities
358.0M
↑ 16.18%
FY21Y/Y Change
Total Assets
152.5M
↑ 135.5%
Total Liabilities
6.6M
↓ 98.16%
FY22Y/Y Change
Total Assets
124.9M
↓ 18.1%
Total Liabilities
15.8M
↑ 139.14%
Q2 FY22Q/Q Change
Total Assets
134.0M
↓ 7.18%
Total Liabilities
6.9M
↓ 9.35%
Q3 FY22Q/Q Change
Total Assets
126.6M
↓ 5.57%
Total Liabilities
8.3M
↑ 20.91%
Q4 FY22Q/Q Change
Total Assets
124.9M
↓ 1.29%
Total Liabilities
15.8M
↑ 89.11%
Q1 FY23Q/Q Change
Total Assets
122.7M
↓ 1.8%
Total Liabilities
23.0M
↑ 46.28%
Q2 FY23Q/Q Change
Total Assets
115.0M
↓ 6.29%
Total Liabilities
25.0M
↑ 8.5%
Q3 FY23Q/Q Change
Total Assets
106.4M
↓ 7.45%
Total Liabilities
23.6M
↓ 5.73%
FY19Y/Y Change
Operating Cash Flow
-12.8M
-
Investing Cash Flow
-106.0K
-
Financing Cash Flow
29.5M
-
FY20Y/Y Change
Operating Cash Flow
-16.1M
↑ 25.9%
Investing Cash Flow
-311.0K
↑ 193.4%
Financing Cash Flow
49.8M
↑ 68.48%
FY21Y/Y Change
Operating Cash Flow
-27.7M
↑ 72.29%
Investing Cash Flow
-1.2M
↑ 280.39%
Financing Cash Flow
111.9M
↑ 124.74%
FY22Y/Y Change
Operating Cash Flow
-42.7M
↑ 53.89%
Investing Cash Flow
-685.0K
↓ 42.1%
Financing Cash Flow
7.5M
↓ 93.3%
Q1 FY22Q/Q Change
Operating Cash Flow
-10.6M
↑ 51.73%
Investing Cash Flow
-293.0K
↓ 45.54%
Financing Cash Flow
48.0K
↓ 100.23%
Q2 FY22Q/Q Change
Operating Cash Flow
-10.1M
↓ 5.15%
Investing Cash Flow
-49.0K
↓ 83.28%
Financing Cash Flow
321.0K
↑ 568.75%
Q3 FY22Q/Q Change
Operating Cash Flow
-11.1M
↑ 9.9%
Investing Cash Flow
-264.0K
↑ 438.78%
Financing Cash Flow
7.0K
↓ 97.82%
Q4 FY22Q/Q Change
Operating Cash Flow
-10.8M
↓ 2.3%
Investing Cash Flow
-79.0K
↓ 70.08%
Financing Cash Flow
7.1M
↑ 101571.43%
Q1 FY23Q/Q Change
Operating Cash Flow
-10.2M
↓ 5.46%
Investing Cash Flow
-240.0K
↑ 203.8%
Financing Cash Flow
7.6M
↑ 6.34%
Q2 FY23Q/Q Change
Operating Cash Flow
-12.8M
↑ 24.97%
Investing Cash Flow
-143.0K
↓ 40.42%
Financing Cash Flow
473.0K
↓ 93.75%

Technicals Summary

Sell

Neutral

Buy

Cvrx Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cvrx Inc
Cvrx Inc
60.94%
73.28%
51.8%
18.23%
18.23%
Stryker Corporation
Stryker Corporation
7.03%
7.0%
22.49%
27.12%
71.25%
Dexcom, Inc.
Dexcom, Inc.
24.5%
-4.85%
-1.26%
40.0%
241.52%
Boston Scientific Corp.
Boston Scientific Corp.
6.89%
8.34%
20.47%
64.39%
45.78%
Abbott Laboratories
Abbott Laboratories
9.3%
0.65%
-2.97%
-3.02%
41.21%
Medtronic Plc
Medtronic Plc
10.96%
-4.5%
0.46%
-29.59%
-19.0%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cvrx Inc
Cvrx Inc
0.14
NA
NA
-2.1
-0.42
-0.24
0.0
3.98
Stryker Corporation
Stryker Corporation
43.5
43.5
2.85
10.41
0.15
0.07
0.01
47.13
Dexcom, Inc.
Dexcom, Inc.
124.12
124.12
11.34
1.42
0.18
0.06
0.0
5.87
Boston Scientific Corp.
Boston Scientific Corp.
67.84
67.84
2.53
2.01
0.07
0.04
0.02
12.89
Abbott Laboratories
Abbott Laboratories
34.99
34.99
18.76
4.44
0.14
0.06
0.02
21.59
Medtronic Plc
Medtronic Plc
25.64
25.64
3.04
5.28
0.08
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cvrx Inc
Cvrx Inc
Buy
$419.4M
18.23%
0.14
-121.06%
Stryker Corporation
Stryker Corporation
Buy
$111.6B
71.25%
43.5
13.0%
Dexcom, Inc.
Dexcom, Inc.
Buy
$43.1B
241.52%
124.12
11.08%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$81.5B
45.78%
67.84
8.93%
Abbott Laboratories
Abbott Laboratories
Buy
$178.6B
41.21%
34.99
12.92%
Medtronic Plc
Medtronic Plc
Buy
$105.1B
-19.0%
25.64
12.84%

Institutional Holdings

  • Johnson & Johnson

    16.79%

  • NEA Management Company, LLC

    11.39%

  • Balyasny Asset Management LLC

    3.81%

  • BlackRock Inc

    3.38%

  • Vanguard Group Inc

    2.63%

  • State Street Corporation

    2.45%

Company Information

cvrx is a private company located in minneapolis, minnesota. the company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. the barostim neo™ uses cvrx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. the barostim neo can be adjusted to meet each patient’s individual therapy needs.

Organization
Cvrx Inc
Employees
160
CEO
Mr. Nadim Yared
Industry
Healthcare

Discover More

FAQs